CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+14.41%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$209M
AUM Growth
–
Cap. Flow
+$209M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
59.43%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Amgen
AMGN
|
$16.5M |
| 2 |
Merck
MRK
|
$14.8M |
| 3 |
Amicus Therapeutics
FOLD
|
$13.4M |
| 4 |
Insmed
INSM
|
$12.8M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$12.5M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $16.5M | 7.9% |
+57,381
| New | +$16.5M |
|
|
2
Merck
MRK
$210B
| $14.8M | 7.09% |
+136,098
| New | +$14.8M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $13.4M | 6.43% |
+947,418
| New | +$13.4M |
|
|
4
Insmed
INSM
$28.8B
| $12.8M | 6.13% |
+413,499
| New | +$12.8M |
|
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12.5M | 5.99% |
+129,906
| New | +$12.5M |
|
6
Roivant Sciences
ROIV
$8.15B
| $11.2M | 5.37% |
+1,000,000
| New | +$11.2M |
|
7
Exelixis
EXEL
$10.1B
| $11.1M | 5.3% |
+462,305
| New | +$11.1M |
|
8
Teva Pharmaceuticals
TEVA
$21.1B
| $11.1M | 5.3% |
+1,061,668
| New | +$11.1M |
|
9
Royalty Pharma
RPRX
$15.6B
| $10.4M | 4.97% |
+370,000
| New | +$10.4M |
|
10
Acadia Pharmaceuticals
ACAD
$4.38B
| $10.4M | 4.95% |
+330,973
| New | +$10.4M |
|
11
BioCryst Pharmaceuticals
BCRX
$1.74B
| $9.12M | 4.36% |
+1,521,812
| New | +$9.12M |
|
12
Halozyme
HALO
$8.56B
| $8.89M | 4.25% |
+240,448
| New | +$8.89M |
|
13
Perrigo
PRGO
$3.27B
| $8.37M | 4% |
+260,000
| New | +$8.37M |
|
14
Pfizer
PFE
$141B
| $7.63M | 3.65% |
+265,000
| New | +$7.63M |
|
15
Bristol-Myers Squibb
BMY
$96B
| $7.18M | 3.43% |
+140,000
| New | +$7.18M |
|
16
CRISPR Therapeutics
CRSP
$4.71B
| $6.73M | 3.22% |
+107,500
| New | +$6.73M |
|
17
Viridian Therapeutics
VRDN
$1.5B
| $6.7M | 3.2% |
+307,721
| New | +$6.7M |
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $6.46M | 3.09% |
+108,000
| New | +$6.46M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $5.51M | 2.63% |
+677,350
| New | +$5.51M |
|
20
Cabaletta Bio
CABA
$133M
| $5.22M | 2.5% |
+230,000
| New | +$5.22M |
|
21
Prestige Consumer Healthcare
PBH
$3.35B
| $5.2M | 2.49% |
+85,000
| New | +$5.2M |
|
22
BridgeBio Pharma
BBIO
$9.89B
| $4.17M | 1.99% |
+103,324
| New | +$4.17M |
|
23
Arcus Biosciences
RCUS
$1.13B
| $3.68M | 1.76% |
+192,667
| New | +$3.68M |
|